Bringing 3rd generation, nanopore sequencing to healthcare to solve…
Shield Bio is a precision medicine company with a proprietary platform that enables reliable nanopore sequencing in under a minute, in a clinical setting. It is focused on bringing 3rd generation or "nanopore" sequencing into clinical use to deliver on the promise of precision medicine. Shield is initially using the technology to improve the treatment of infectious disease and address the unmet clinical need of sepsis, which kills 300,000 people a year in the US alone. Shield Bio is a Y Combinator company (Summer 2016). YC-listed status: Inactive.